FDA’s accelerated approval of Biogen’s aducanumab may ease path for Seattle’s Athira Pharma as ATH-1017 advances
The FDA granted accelerated approval to Biogen’s aducanumab, the first new Alzheimer’s drug in nearly 20 years, a decision that could ease regulatory pathways for other companies like Seattle-based Athira Pharma and lifted Athira’s stock about 4%. Athira CEO Leen Kawas said the approval brings optimism as the company advances its late-stage candidate ATH-1017, a regenerative therapy targeting HGF to repair neuronal connections.